Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinical... - PubMed - NCBI

Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinical... - PubMed - NCBI

Mod Pathol. 2016 Sep 9. doi: 10.1038/modpathol.2016.145. [Epub ahead of print]

Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.

Geurts-Giele WR1, van Verschuer VM2, van Deurzen CH1, van Diest PJ3, Pedrosa RM1, Collée JM4, Koppert LB2, Seynaeve C5, Dinjens WN1.

Author information

Abstract

Female BRCA1/2 mutation carriers affected with breast and/or ovarian cancer may develop new tumor deposits over time. It is of utmost importance to know the clonal relationships between multiple tumor localizations, enabling differentiation between multiple primaries or metastatic disease with consequences for therapy and prognosis. We evaluated the value of targeted next generation sequencing in the diagnostic workup of BRCA1/2 mutation carriers with ≥2 tumor localizations and uncertain tumor origins. Forty-two female BRCA1/2 mutation carriers with ≥2 tumor localizations were selected. Patients with inconclusive tumor origin after histopathological revision were 'cases'; patients with certain tumor origin of ≥3 tumors served as 'controls'. Tumors of cases and controls were analyzed by targeted next generation sequencing using a panel including CDKN2A, PTEN and TP53, hotspot mutation sites for 27 different genes and 143 single nucleotide polymorphisms for detection of loss of heterozygosity. Based on prevalence of identical or different mutations and/or loss of heterozygosity patterns, tumors were classified as 'multiple primaries' or 'one entity'. Conventional histopathology yielded a conclusive result in 38/42 (90%) of patients. Four cases and 10 controls were analyzed by next generation sequencing. In 44 tumor samples, 48 mutations were found; 39 (81%) concerned TP53 mutations. In all 4 cases, the intra-patient clonal relationships between the tumor localizations could be unequivocally identified by molecular analysis. In all controls, molecular outcomes matched the conventional histopathological results. In most BRCA1/2 mutation carriers with multiple tumors routine pathology work-up is sufficient to determine tumor origins and relatedness. In case of inconclusive conventional pathology results, molecular analyses using next generation sequencing can reliably determine clonal relationships between tumors, enabling optimal treatment of individual patients.Modern Pathology advance online publication, 9 September 2016; doi:10.1038/modpathol.2016.145.

PMID:

 

27612322

 

DOI:

 

10.1038/modpathol.2016.145

[PubMed - as supplied by publisher]

Public Health Genomics Knowledge Base (v1.2)

OVARIAN CANCER MONTH

Last Updated: Sep 15, 2016

• In honor of Ovarian Cancer Awareness Month
  G Hurst, Cure today, Sepetember 2016
• Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.
  Geurts-Giele Willemina R R, et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016 9
• Finding all BRCA pathogenic mutation carriers: best practice models.
  Hoogerbrugge Nicoline et al. European journal of human genetics : EJHG 2016 Sep S19-26
• Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
  Prodosmo Andrea, et al. Journal of experimental & clinical cancer research : CR 2016 0 (1) 135
• Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
  Lawrenson Kate, et al. Nature communications 2016 0 12675
• The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.
  Konopka Bozena, et al. Oncotarget 2016 9
• BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
  Chun Danielle S et al. Familial cancer 2016 Sep
• Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.
  Carron Juliana, et al. Medical oncology (Northwood, London, England) 2016 10 (10) 112
• Low-grade serous ovarian cancer: A review.
  Kaldawy Anis, et al. Gynecologic oncology 2016 8
• Ready to clone: CNV detection and breakpoint fine-mapping in breast and ovarian cancer susceptibility genes by high-resolution array CGH.
  Hackmann Karl, et al. Breast cancer research and treatment 2016 8
• Association between BHMT gene rs3733890 polymorphism and cancer risk: evidence from a meta-analysis.
  Xu Yue, et al. OncoTargets and therapy 2016 0 5225-33
• Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.
  Tanakaya Kohji et al. Anticancer research 2016 Apr 36(4) 1985-9
• High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
  Rashid Muhammad Usman, et al. BMC cancer 2016 0 (1) 673
• Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
  Pinto Pedro, et al. Breast cancer research and treatment 2016 8
• All women with ovarian cancer should be offered genetic testing – so why aren’t they? 
  E Smith, Science Blogs, August 17, 2016

• CDC Information (9)
• CDC-Authored Pub (7)

• Human (52)
• Pathogen (0)

• Human (1497)
• Pathogen (0)

• Human (226)
• Pathogen (0)

• Guidelines (11)
• Tier Table (4)
• Synthesis (14)

• Huamn (112)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB